Peripheral T-Cell Lymphomas–Not Otherwise Specified: A Shrinking Entity?
Search for other papers by Steven M. Horwitz in
Current site
Google Scholar
PubMed
Peripheral T-cell lymphomas–not otherwise specified (PTCL-NOS) is a broad category of biologically and clinically heterogeneous diseases, which likely does not have a single treatment paradigm. Understanding of subtype-specific approaches is leading to more individualized therapy. There are also therapeutic vulnerabilities to target, such as CD30, JAK/STAT pathway, and epigenetic modifiers, that may cross different histologic subtypes. As new therapies evolve, however, it is important to understand in which situations current standard treatments work, because some of these treatments, such as combination chemotherapy, are potentially curative for a subset of patients. For certain populations, adding to these chemotherapy backbones will produce the best results. For other populations, entirely new approaches may be appropriate. Future treatment advances will, in part, be made by enriching populations based on their likelihood of response to specific therapies and utilizing biomarker-driven or biomarker-informed strategies.
Disclosures: Dr. Horwitz had disclosed that he has received consulting fees from Astex Pharmaceuticals; Celgene Corporation; Janssen Pharmaceutica Products, LP; Kura Oncology, Inc.; Kyowa Hakko Kirin Co., Ltd.; ADCT; C4 Therapeutics; Curio; Myeloid Therapeutics; Verastem; Seattle Genetics, Inc.; and Takeda Pharmaceuticals North America, Inc. He has also received grant/research support from Celgene Corporation; Daiichi-Sankyo Co.; Forty Seven, Inc.; ADCT; Aileron; Corvus; Trillium; Verastem; Portola Pharmaceuticals, Inc.; and Seattle Genetics, Inc.
© 2019-2024 National Comprehensive Cancer Network